A phase 1 trial of the histone deacetylase inhibitor AR-42 in patients with neurofibromatosis type 2-associated tumors and advanced solid malignancies

被引：0
作者：
Katharine A. Collier
Hugo Valencia
Herbert Newton
Erinn M. Hade
Douglas W. Sborov
Robert Cavaliere
Ming Poi
Mitch A. Phelps
Sophia G. Liva
Christopher C. Coss
Jiang Wang
Soun Khountham
Paul Monk
Charles L. Shapiro
Richard Piekarz
Craig C. Hofmeister
D. Bradley Welling
Amir Mortazavi
机构：
[1] The Ohio State University and The Comprehensive Cancer Center,Division of Medical Oncology, Department of Internal Medicine
[2] The Ohio State University and The Comprehensive Cancer Center,Division of Hematology, Department of Internal Medicine
[3] The Ohio State University and The Comprehensive Cancer Center,Division of Neuro
[4] The Ohio State University,Oncology, Departments of Neurology and Neurosurgery
[5] Huntsman Cancer Institute,Center for Biostatistics, Department of Biomedical Informatics
[6] University of Utah,Division of Hematology and Hematologic Malignancies
[7] Baptist MD Anderson,Division Neuro
[8] The Ohio State University and The Comprehensive Cancer Center,Oncology, Department of Cancer Medicine
[9] National Cancer Institute/Cancer Therapy Evaluation Program,College of Pharmacy
[10] Winship Cancer Institute of Emory University,Division of Hematology, Department of Hematology and Medical Oncology
[11] Massachusetts Eye and Ear Infirmary and Massachusetts General Hospital,Department of Otolaryngology Head and Neck Surgery, Harvard Medical School
来源：
Cancer Chemotherapy and Pharmacology | 2021年 / 87卷
关键词：
Histone deacetylase inhibitor; Neurofibromatosis type 2; Phase 1; Pharmacokinetics; Solid tumor;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：599 / 611
页数：12
相关论文
共 896 条
[1]  
Choudhary C(2009)Lysine acetylation targets protein complexes and co-regulates major cellular functions Science 325 834-840
[2]  
Kumar C(2014)Erasers of histone acetylation: the histone deacetylase enzymes Cold Spring Harb Perspect Biol 6 a018713-27
[3]  
Gnad F(2016)HDACs and HDAC inhibitors in cancer development and therapy Cold Spring Harb Perspect Med 150 12-5432
[4]  
Nielsen ML(2012)Cancer epigenetics: from mechanism to therapy Cell 26 5420-3115
[5]  
Rehman M(2007)Histone deacetylases and cancer Oncogene 2011 475641-5417
[6]  
Walther TC(2011)Histone deacetylase inhibitors in the treatment of hematological malignancies and solid tumors J Biomed Biotechnol 25 3109-969
[7]  
Olsen JV(2007)Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma J Clin Oncol 27 5410-1203
[8]  
Mann M(2009)Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma J Clin Oncol 19 964-776
[9]  
Seto E(2008)Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma Ann Oncol 29 1198-394
[10]  
Yoshida M(2011)Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin's lymphoma and mantle cell lymphoma J Clin Oncol 165 768-2203
12345678910